On August 27, 2020 Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, reported that CEO, Timothy C. Rodell, MD, is scheduled to present to a live audience at the LD Micro 500 virtual investor conference on Thursday, September 3, 2020 at 11:40 am Pacific Time (2:40 pm ET), and will be available for one-on-one meetings with investors throughout the day on September 3, 2020 (Press release, Aethlon Medical, AUG 27, 2020, View Source [SID1234564125]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be aired live and available for replay at the investor relations section of Aethlon Medical’s website at www.aethlonmedical.com.

The LD Micro 500 will take place September 1-4 and will feature some of the most prominent companies in the micro-cap world, with 500 companies expected to provide updates. Register here: View Source Those wishing to listen to the presentation over the phone can dial into 877-407-6180 (domestic calls) or 201-689-8050 (international calls).

Replays of the presentation will be available for three months. The reply can be accessed through View Source

On August 27, 2020 VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) disorders, reported that the Company will be presenting at the LD Micro 500 Virtual Conference to be held September 1-4, 2020 (Press release, VistaGen Therapeutics, AUG 27, 2020, View Source [SID1234564124]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

VistaGen’s Chief Executive Officer, Shawn Singh, is scheduled to present on Thursday, September 3, 2020, at 11 a.m. EDT / 8 a.m. PDT. This presentation will be webcast live, and all investors are welcome to watch by registering at View Source

VistaGen’s conference profile can be viewed at View Source

On August 27, 2020 The National Comprehensive Cancer Network (NCCN) reported this year’s NCCN Annual Congress: Hematologic Malignancies will be fully online and open to all attendees at no cost (Press release, NCCN, AUG 27, 2020, View Source [SID1234564123]). This annual gathering provides instruction from world-renowned experts for determining the best emerging techniques and practices for various blood cancers, including leukemia, lymphoma, and multiple myeloma. The virtual event will provide numerous opportunities for physicians, nurses, pharmacists, and other health professionals to earn continuing education credits, interact with experts, and network with peers.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The NCCN Virtual Annual Congress: Hematologic Malignancies will take place on October 9-10, 2020 with the corresponding NCCN Virtual Nursing Forum taking place on October 8, 2020.

The programs will include diagnostic and therapeutic advances, NCCN Guidelines updates, controversies in treatment, and currently salient topics such as: Navigating the Jargon of Molecular Testing, Implications of Biology on Treatment, Considering CAR T for All, Optimizing Outpatient Care, and Managing Cardiac Complications. The complete agenda can be viewed at NCCN.org/hem.

"The rapid pace of change in cancer care can pose challenges for clinicians trying to stay up-to-date on how to optimize patient outcomes," said event co-chair Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center. "We’re eager to reduce any knowledge and practice gaps by sharing information on the therapeutic advances that help us individualize treatment selection, minimize toxicities, and manage adverse events."

"The NCCN Annual Congress for Hematologic Malignancies offers expert analysis of the latest clinical trial data," said co-chair Ranjana H. Advani, MD, Stanford Cancer Institute. "Patients benefit when providers are well equipped to utilize cutting-edge guidelines. These comprehensive presentations, case studies, and interactive discussions will allow clinicians to stay abreast of advances in the evolving diagnostic and treatment landscape."

The virtual format for the congress will provide opportunities for participants to engage with faculty in real-time and also include an online exhibit hall and breakout rooms for networking with colleagues.

"Our new platform allows us to make vital cancer information more accessible than ever, as we adjust for the ongoing COVID-19 pandemic," explained Robert W. Carlson, MD, Chief Executive Officer, NCCN. "We look forward to having attendees from around the world and throughout the oncology ecosystem join us from the convenience of their home or office without the need for travel."

Anyone who is not able to join the interactive sessions in real-time will have an opportunity to view recordings from the webcasts from November 1, 2020 through October 31, 2021 at education.nccn.org. A related Case of the Week series will also launch after the Congress. Join the conversation online with the hashtag #NCCNhem2020.

On August 27, 2020 Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA, reported a collaborative agreement with Mass General Cancer Center (MGCC) of Massachusetts General Hospital, related to an investigator-initiated multi-center, Phase II randomized clinical trial of Ribociclib (Kisqali), a CDK4/6 inhibitor, for the treatment of ER-positive breast cancer (LEADER), the first circulating tumor DNA (ctDNA)-based study of a CDK4/6 inhibitor in ER-positive early stage breast cancer (Press release, Natera, AUG 27, 2020, View Source [SID1234564122]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

LEADER (part II) will randomize patients who have localized post-menopausal breast cancer with detectable ctDNA after surgery as evidence of minimal residual disease (MRD), and will determine tumor molecular response after Ribociclib in combination with endocrine therapy versus endocrine therapy alone. Natera’s Signatera test will be used to determine patient enrollment eligibility based on presence of ctDNA via longitudinal monitoring and to evaluate response based on ctDNA clearance as the primary endpoint.

"With the overwhelming evidence that patients with detectable ctDNA are at high risk for relapse, our goal is to investigate a new treatment strategy for these patients and reduce risk of disease recurrence," said Aditya Bardia, MD, MPH, the study’s principal investigator from MGCC, Harvard Medical School. "Since the LEADER trial is in the MRD setting, it is critical to use a highly sensitive assay."

Breast cancer remains the second leading cause of cancer death in women in the United States,1 and the U.S. Food and Drug Administration (FDA) has approved Ribociclib in combination with aromatase inhibitors as a first-line treatment option for advanced/metastatic (stage IV) disease.

"We are proud to partner with Massachusetts General Hospital on this exciting new approach of using Signatera personalized ctDNA analysis for enrollment and evaluation of treatment response to CDK4/6 inhibitors in the MRD setting," said Alexey Aleshin, MD, MBA, Natera’s Senior Medical Director for Oncology. "We believe this collaboration may pave the way for more trials using ctDNA to study the effectiveness of an investigational drug in early stage breast cancer."

About Signatera

Signatera is a custom-built ctDNA test for treatment monitoring and MRD assessment in patients previously diagnosed with cancer. The test is available for clinical and research use, and it was granted Breakthrough Device Designation by the FDA in 2019. The Signatera test is personalized and tumor-informed, providing each individual with a customized blood test tailored to fit the unique signature of clonal mutations found in that individual’s tumor. This maximizes accuracy for detecting the presence or absence of residual disease in a blood sample, even at levels down to a single tumor molecule in a tube of blood. Unlike a standard liquid biopsy, Signatera is not intended to match patients with any particular therapy. Rather, it is intended to detect and quantify how much cancer is left in the body, to detect recurrence earlier and to help optimize treatment decisions. Signatera’s test performance has been clinically validated in multiple cancer types including colorectal, non-small cell lung, breast, and bladder cancers. Signatera has been developed and its performance characteristics determined by Natera, the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA). CAP accredited, ISO 13485 certified, and CLIA certified.

On August 27, 2020 HJB, a biologics Contract Development and Manufacturing Organization (CDMO) committed to quality, reliability and speed for each and every CMC package delivered to its partners, reported it enters into a strategic partnership for CMC development and manufacturing with Ansun Biopharma ("Ansun"), a clinical stage biopharmaceutical company, on its therapeutic biologics pipeline (Press release, HJB pharma, AUG 27, 2020, View Source [SID1234564121]). The first program is expecting to submit an Investigational New Drug (IND) application in 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the agreement, Ansun will have the ability to leverage HJB’s comprehensive expertise and capacities from cell line development, process and assay development to GMP manufacturing, IND-enabling full-service package and clinical and commercial supply in the global territory for the next three years. The agreement provides a strong support for Ansun’s development goals and a potential significant acceleration of its portfolio to market.

"We are very excited about this strategic agreement with HJB, which we consider to be a key piece of foundation for advancing Ansun’s strong biologics pipeline in the coming years," said, George Wang, Sc.D, Chief Technology Officer of Ansun. "As the company continues to expand its pipeline by advancing more early stage assets into clinical development, a partnership with a reliable and capable CDMO such as HJB will accelerate the successful transition of the promising sciences into clinical benefit for global patients."

"We are proud to be selected as the CMC development and manufacturing partner of Ansun to support expedited and high-quality packages of their innovative biologics programs," said Jerry Yang, Ph.D., General Manager of HJB. "A robust and top-notch supply chain is fundamental to biotech to achieve speed and success to market. The recent global disruption on drug development and manufacturing capacities due to a pandemic has made it even more pressing for companies to secure the much needed capacities while remaining focused and agile. We will continue creating value as a dedicated CDMO by empowering all our global and domestic partners to bring better treatments to the patients."

Since its Hangzhou facility’s first GMP run in mid-2018, HJB has taken more than 20 CDMO projects, delivered 30 batches of GMP products and has been recognized by its global partners for quality, reliability and speed. Currently, HJB’s comprehensive capabilities include cell line and cell bank development, process and formulation development, technology transfer and optimization as well as GMP manufacturing, with three DS production lines (500 – 2,000L), and a DP fill-and-finish line. HJB has served more than double amount of client programs during the first half of 2020 despite a minimal disruption of operation due to COVID-19. The performance demonstrated HJB’s commitment to execution, delivery and quality system.